Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Independents are still investing in refits, says IPF

Independent pharmacies are investing in keeping their premises up to date despite financial difficulties facing some businesses, a survey has suggested.

More than half of pharmacies polled by the Independent Pharmacy Federation (IPF) had undergone a refit in the past five years. A further 18 per cent had refitted within the past 10 years, the poll showed.

More than two thirds of those polled reported that they had invested up to £40,000 in their refits.

The results showed independents were "keeping up to date and providing the right environment for patients and staff", said IPF chief executive Claire Ward.

"Independents need to be at the cutting edge of the sector… so it is good to see that our members are still able to provide a modern pharmacy environment," Ms Ward said.

The findings demonstrate that independent pharmacists are able to offer the right environment for services, she added.

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD014427

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel